HEPLISAV-B is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary TLR9 agonist to enhance the immune response. Subject to approval by the U.S. Food and Drug Administration, we plan to launch HEPLISAV-B in late 2016.

Learn More › 

Toll-like Receptor (TLR) Platform

Our TLR platform is broadly applicable across multiple diseases including infectious diseases, cancer and asthma.

Learn More ›

Our values

At Dynavax we are proud of the work we do. Our corporate values provide the foundation of our culture and how we operate as a company.

Learn More ›